Du Yue, Li Qing, Dou Yikai, Wang Min, Wang Yu, Yan Yushun, Fan Huanhuan, Yang Xiao, Ma Xiaohong
Mental Health Center and Laboratory of Psychiatry, West China Hospital of Sichuan University, 610041, Chengdu, China.
Heliyon. 2024 Apr 1;10(7):e28918. doi: 10.1016/j.heliyon.2024.e28918. eCollection 2024 Apr 15.
Buspirone, a 5-hydroxytryptamine 1A (5-HT1A) receptor agonist, has been investigated for its use in various diseases. However, knowledge about its side effects and potential cognitive benefits in different conditions is limited. Cognitive impairment is also a prevalent symptom in many diseases, yet effective treatments are still lacking. Therefore, to explore the potential side effects of buspirone and the possible cognitive benefits of buspirone, we conducted a comprehensive search of several databases, including PubMed, Embase, Web of Science, Cochrane Review, Cochrane Trial, and ClinicalTrials.gov, to identify eligible randomized clinical trials. Our primary outcome measures included both side effects (adverse events) and cognitive benefits. For continuous variables, we utilized effect size with a 95% confidence interval (CI), whereas for dichotomous variables, we used odds ratios (OR) with a 95% CI. In total, 16 studies were included in this analysis, with 13 studies reporting on buspirone's side effects and 4 studies focusing on cognitive tasks. In terms of side effects, buspirone exhibited a higher rate of dizziness (OR = 4.66, 95% CI: 2.07-10.47), constipation (OR = 4.11, 95% CI: 1.34-12.55), and gastric distress (OR = 1.97, 95% CI: 1.03-3.78) than the placebo group. Regarding cognitive functions, buspirone showed significant benefits (g = 0.20, 95% CI: 0.06-0.34) while the placebo did not. Subgroup analysis indicated superior performance in visual learning and memory (g = 0.49, 95% CI: 0.21-0.78), logical reasoning (g = 0.42, 95% CI: 0.14-0.71), and attention (g = 0.37, 95% CI: 0.13-0.61) when compared to placebo. Our findings indicated that participants in the buspirone group experienced side effects of dizziness, constipation, and gastric distress in different diseases. Despite these adverse events, however, buspirone demonstrated significant cognitive benefits, particularly in the domains of visual learning and memory, logical reasoning, and attention.
丁螺环酮是一种5-羟色胺1A(5-HT1A)受体激动剂,已针对其在各种疾病中的应用进行了研究。然而,关于其在不同情况下的副作用和潜在认知益处的了解有限。认知障碍也是许多疾病中普遍存在的症状,但仍缺乏有效的治疗方法。因此,为了探索丁螺环酮的潜在副作用和可能的认知益处,我们对多个数据库进行了全面检索,包括PubMed、Embase、科学网、Cochrane系统评价、Cochrane试验和ClinicalTrials.gov,以确定符合条件的随机临床试验。我们的主要结局指标包括副作用(不良事件)和认知益处。对于连续变量,我们使用效应量及95%置信区间(CI),而对于二分变量,我们使用比值比(OR)及95%CI。本分析共纳入16项研究,其中13项研究报告了丁螺环酮的副作用,4项研究关注认知任务。在副作用方面,与安慰剂组相比,丁螺环酮出现头晕(OR = 4.66,95%CI:2.07 - 10.47)、便秘(OR = 4.11,95%CI:1.34 - 12.55)和胃部不适(OR = 1.97,95%CI:1.03 - 3.78)的发生率更高。在认知功能方面,丁螺环酮显示出显著益处(g = 0.20,95%CI:0.06 - 0.34),而安慰剂则没有。亚组分析表明,与安慰剂相比,丁螺环酮在视觉学习和记忆(g = 0.49,95%CI:0.21 - 0.78)、逻辑推理(g = 0.42,95%CI:0.14 - 0.71)和注意力(g = 0.37,95%CI:0.13 - 0.61)方面表现更优。我们的研究结果表明,丁螺环酮组的参与者在不同疾病中出现了头晕、便秘和胃部不适等副作用。然而,尽管有这些不良事件,丁螺环酮仍显示出显著的认知益处,特别是在视觉学习和记忆、逻辑推理以及注意力方面。